Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28541315
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28541315
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Nature
2017 ; 545
(7655
): 423-431
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Therapeutic T cell engineering
#MMPMID28541315
Sadelain M
; Rivière I
; Riddell S
Nature
2017[May]; 545
(7655
): 423-431
PMID28541315
show ga
Genetically engineered T cells are powerful new medicines, offering hope for
curative responses in patients with cancer. Chimaeric antigen receptors (CARs)
are a class of synthetic receptors that reprogram lymphocyte specificity and
function. CARs targeting CD19 have demonstrated remarkable potency in B cell
malignancies. Engineered T cells are applicable in principle to many cancers,
pending further progress to identify suitable target antigens, overcome
immunosuppressive tumour microenvironments, reduce toxicities, and prevent
antigen escape. Advances in the selection of optimal T cells, genetic
engineering, and cell manufacturing are poised to broaden T-cell-based therapies
and foster new applications in infectious diseases and autoimmunity.